ERBB2 and breast carcinoma: Incidentally, the addition of FOXA1 to our analysis (over and above the combination of mean JAM-A and HER2 mRNA expression) had an interesting impact on overall survival (OS) figures in breast cancer patients, with high mean expression of JAM-A, HER2 and FOXA1 achieving a statistically significant positive correlation with poorer overall survival in both HER2-positive patients and the entire breast cancer patient population, alongside a significant negative correlation in HER2-negative patients (Supplemental Figure S9).